Humana (NYSE:HUM) had its price target lifted by Citigroup from $340.00 to $350.00 in a research note published on Thursday, Stock Target Advisor reports. The brokerage currently has a buy rating on the insurance provider’s stock.
Other analysts also recently issued reports about the stock. Mizuho started coverage on shares of Humana in a research report on Thursday, October 17th. They set a buy rating and a $316.00 price objective on the stock. Morgan Stanley cut their price objective on shares of Humana from $342.00 to $337.00 and set an overweight rating on the stock in a research report on Thursday, September 26th. BMO Capital Markets downgraded shares of Humana from an outperform rating to a market perform rating and cut their price objective for the company from $345.00 to $290.00 in a research report on Monday, September 30th. Berenberg Bank reissued a buy rating on shares of Humana in a research report on Monday, October 21st. Finally, UBS Group increased their price objective on shares of Humana from $266.00 to $317.00 and gave the company a neutral rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating and fourteen have assigned a buy rating to the stock. Humana has an average rating of Buy and an average price target of $322.63.
HUM stock traded up $2.44 during trading on Thursday, hitting $317.58. 1,173,375 shares of the stock traded hands, compared to its average volume of 1,220,728. Humana has a 1 year low of $225.65 and a 1 year high of $342.03. The firm’s 50 day moving average is $277.48 and its two-hundred day moving average is $270.93. The stock has a market cap of $39.82 billion, a price-to-earnings ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.75 and a quick ratio of 1.75.
Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 6th. The insurance provider reported $5.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. Humana had a net margin of 4.13% and a return on equity of 22.47%. The company had revenue of $16.24 billion for the quarter, compared to the consensus estimate of $16.15 billion. During the same period in the prior year, the firm posted $4.58 EPS. Humana’s revenue for the quarter was up 14.3% on a year-over-year basis. As a group, analysts anticipate that Humana will post 17.75 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.69%. The ex-dividend date is Monday, December 30th. Humana’s dividend payout ratio is currently 15.12%.
In other Humana news, insider Brian P. Leclaire sold 7,239 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the transaction, the insider now owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.54% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of HUM. Endurance Wealth Management Inc. lifted its stake in Humana by 354.5% during the 3rd quarter. Endurance Wealth Management Inc. now owns 100 shares of the insurance provider’s stock valued at $26,000 after acquiring an additional 78 shares during the period. Whittier Trust Co. bought a new position in shares of Humana in the 2nd quarter worth approximately $27,000. Next Capital Management LLC bought a new position in shares of Humana in the 2nd quarter worth approximately $27,000. Quest Capital Management Inc. ADV bought a new position in shares of Humana in the 3rd quarter worth approximately $30,000. Finally, Advantage Investment Management LLC lifted its stake in shares of Humana by 287.1% in the 2nd quarter. Advantage Investment Management LLC now owns 120 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 89 shares during the period. Institutional investors and hedge funds own 92.93% of the company’s stock.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Story: Why is the price target of stocks important?
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.